Related references
Note: Only part of the references are listed.Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
B7H4 expression in tumor cells impairs CD8 T cell responses and tumor immunity
Linlin Zhou et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
The single-cell pathology landscape of breast cancer
Hartland W. Jackson et al.
NATURE (2020)
A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer
Johanna Wagner et al.
CELL (2019)
Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer
Mustapha Abubakar et al.
MODERN PATHOLOGY (2019)
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
Leonie Voorwerk et al.
NATURE MEDICINE (2019)
Current Landscape of Immunotherapy in Breast Cancer: A Review
Sylvia Adams et al.
JAMA ONCOLOGY (2019)
Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy
Renee Clift et al.
CANCER RESEARCH (2019)
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination
Yosi Gilad et al.
SCIENTIFIC REPORTS (2019)
Contribution of regulatory T cells to cancer: A review
Masoud Najafi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
If we build it they will come: targeting the immune response to breast cancer
Margaret E. Gatti-Mays et al.
NPJ BREAST CANCER (2019)
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel et al.
NATURE REVIEWS CANCER (2019)
Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications
Pascal Jezequel et al.
BREAST CANCER RESEARCH (2019)
Immune gene expression profiling reveals heterogeneity in luminal breast tumors
Bin Zhu et al.
BREAST CANCER RESEARCH (2019)
Checkpoint blockade in the treatment of breast cancer: current status and future directions
Lironne Wein et al.
BRITISH JOURNAL OF CANCER (2018)
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Frederick Arce Vargas et al.
CANCER CELL (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells
Debangshu Samanta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
David R. Gandara et al.
NATURE MEDICINE (2018)
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Moshe Sade-Feldman et al.
CELL (2018)
Small Molecules as PD-1/PD-L1 Pathway Modulators for Cancer Immunotherapy
Peifu Jiao et al.
CURRENT PHARMACEUTICAL DESIGN (2018)
Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer
Rico D. Bense et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer
Rico D. Bense et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Validation of Intratumoral T-bet+ Lymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer
Anna Marie Mulligan et al.
CANCER IMMUNOLOGY RESEARCH (2016)
The immune system and hormone-receptor positive breast cancer: Is it really a dead end?
Maria Vittoria Dieci et al.
CANCER TREATMENT REVIEWS (2016)
The immune microenvironment of breast ductal carcinoma in situ
Elizabeth Thompson et al.
MODERN PATHOLOGY (2016)
Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study
H. Raza Ali et al.
PLOS MEDICINE (2016)
Clinical significance of tumor-infiltrating lymphocytes in breast cancer
Sasha E. Stanton et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups
Dvir Netanely et al.
BREAST CANCER RESEARCH (2016)
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials
M. V. Dieci et al.
ANNALS OF ONCOLOGY (2015)
T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection
Eoin F. McKinney et al.
NATURE (2015)
Molecular and cellular insights into T cell exhaustion
E. John Wherry et al.
NATURE REVIEWS IMMUNOLOGY (2015)
In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
Kurt A. Schalper et al.
CLINICAL CANCER RESEARCH (2014)
An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer
Michael L. Gatza et al.
NATURE GENETICS (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Prognostic significance of FOXP3+tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration
Shuzhen Liu et al.
BREAST CANCER RESEARCH (2014)
Influence of tumour micro-environment heterogeneity on therapeutic response
Melissa R. Junttila et al.
NATURE (2013)
Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
Nicolai Juul Birkbak et al.
PLOS ONE (2013)
CD8(+) lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer
Shuzhen Liu et al.
BREAST CANCER RESEARCH (2012)
Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer
Sahar M. A. Mahmoud et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer
Suet F. Chin et al.
GENOME BIOLOGY (2007)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Share Paper
